Jefferies downgrades Avadel Pharmaceuticals stock to Hold on Alkermes deal
NegativeFinancial Markets

Jefferies has downgraded Avadel Pharmaceuticals' stock to a Hold rating following the recent deal with Alkermes. This decision reflects concerns about the potential impact of the acquisition on Avadel's future performance. Investors should pay attention to how this change might affect the company's market position and overall growth prospects.
— Curated by the World Pulse Now AI Editorial System








